Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | GAPDH | P04406 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619135 | 0.89 | ADORA1 (0.64) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL11443305 | 0.87 | AHCY (0.70) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15798541 | 0.87 | AHCY (0.72) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL2057039 | 0.87 | AHCY (0.72) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15371596 | 0.87 | AHCY (0.72) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15926827 | 0.86 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15788449 | 0.86 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15338536 | 0.86 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL384075 | 0.86 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL41361 | 0.86 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875595-B2 | 5-[6-Amino-2-(2-hydroxy-adamantan-2-ylethynyl)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid cyclopropylamide for the treatment of inflammatory activity in mammalian tissue; A2A adenosine receptor agonist; autoimmune stimulation, allergic diseases, skin diseases, infectious diseases | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-12-03 | — | — | US | disclosed |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-12-03 | — | — | US | disclosed |
| US-7576069-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7442687-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20060217343-A1 | 2-Polycyclic propynyl adenosine analogs having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2006-09-28 | — | — | US | disclosed |
| US-20060217343-A1 | 2-Polycyclic propynyl adenosine analogs having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2006-09-28 | — | — | US | disclosed |
| WO-2006028618-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006028618-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006023272-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006023272-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040889-A1 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | ADENOSINE THERAPEUTICS, L.L.C | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217343-A1 | 2-Polycyclic propynyl adenosine analogs having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | AHCY 1671/4885ADORA1 3/4885SMN1; SMN2 3730/4885 |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | AHCY 1671/4885ADORA1 3/4885SMN1; SMN2 3730/4885 |
| US-20060040889-A1 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | AHCY 1671/4885ADORA1 3/4885SMN1; SMN2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.